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Background: A localized non-surgical delivery of allogeneic human chondrocytes (hChonJ) with irradiated genetically
modified chondrocytes (hChonJb#7) expressing transforming growth factor-β1 (TGF-β1) showed efficacy in
regenerating cartilage tissue in our pre-clinical studies and human Phase I and II clinical trials. These previous
observations led us to investigate the molecular mechanisms of the cartilage regeneration.
Methods: Genetically modified TGF-β1preprotein was evaluated by monitoring cell proliferation inhibition
activity. The effect of modified TGF-β1 on chondrocytes was evaluated based on the type II collagen mRNA
levels and the amount of glycosaminoclycan (GAG) formed around chondrocytes, which are indicative markers
of redifferentiated chondrocytes. Among the cartilage matrix components produced by hChonJb#7 cells, type II
collagen and proteoglycan, in addition to TGF-β1, were also tested to see if they could induce hChonJ redifferentiation.
The ability of chondrocytes to attach to artificially induced defects in rabbit cartilage was tested using fluorescent
markers.
Results: Throughout these experiments, the TGF-β1 produced from hChonJb#7 was shown to be equally as active as
the recombinant human TGF-β1. Type II collagen and GAG production were induced in hChonJ cells by TGF-β1
secreted from the irradiated hChonJb#7 cells when the cells were co-cultured in micro-masses. Both hChonJ and
hChonJb#7 cells could attach efficiently to the defect area in the rabbit cartilage.
Conclusions: This study suggests that the mixture (TG-C) of allogeneic human chondrocytes (hChonJ) and
irradiated genetically modified human chondrocytes expressing TGF-β1 (hChonJb#7) attach to the damaged
cartilage area to produce type II collagen-GAG matrices by providing a continuous supply of active TGF-β1.Background
Deterioration of cartilage leads to osteoarthritis, through
which articular chondrocytes become deformed, or fibril-
lated, losing their cartilage forming function. Additionally,
once damaged or injured, cartilage has limited capability
for self-healing due to its avascular characteristics [1].
Transplantation of autologous or allogeneic chondrocytes,
or mesenchymal stem cells are promising treatments for
cartilage damage [2, 3]. However, due to limited supplies
of autologous or allogeneic chondrocytes and technical* Correspondence: ortholee@tissuegene.com
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chondrocytes, a reliable method for repairing cartilage
damage remains undeveloped [4, 5].
Although small population of other cell type such as
mesenchymal progenitor cells have been observed, ma-
ture chondrocytes are the major cell type which exists in
cartilage and are the ultimate cell type for treating cartil-
age damage [6, 7]. Mature chondrocytes have been
shown to exhibit a continual loss of their chondrocyte
characteristics during extended monolayer expansion
[8]. Expression of type II collagen, one of the prominent
components of cartilage, decreases during the growth of
chondrocytes in two dimensional culture vessels, while
type I collagen increases significantly [9]. The original
round or polygonal shape of chondrocytes also changesicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Yoon et al. BMC Musculoskeletal Disorders  (2015) 16:141 Page 2 of 12to a spindled, fibroblast-like shape which is one of the
characteristics of a “de-differentiated” state. Chondro-
cytes return to a “re-differentiated” state in three dimen-
sional cultures in matrices such as agarose [10]. Because
the response of chondrocytes is sensitive to subtle differ-
ences in surface roughness and surface chemistry, a nat-
ural environment change such as surface damage is also
assumed to affect the characteristics of chondrocytes
[11]. This chondrocyte-matrix interaction plays a con-
tributing role in maintaining and repairing articular
cartilage [12].
The substance of the matrix is considered important
for cartilage regeneration. Cartilage defects treated with
type I collagen matrices showed fibro-cartilage tissue
generation while defects treated with type II collagen
matrices produced hyaline cartilage tissue [13]. In
addition to the matrix, bioactive factors added to chon-
drocytes or mesenchymal stem cells have been used to
maintain the integrity of chondrocytes [14, 15]. A com-
bination of basic fibroblast growth factor (bFGF) and
type I/II collagen matrix showed increased GAG expres-
sion compared with the addition of each component sin-
gly [16]. GAG synthesis was also stimulated by TGF-β1,
which is a known induction factor for the differentiation
of stem cells to cartilage [17, 18].
We have reported that the re-differentiated status of
chondrocytes and induced cartilage regeneration could
be maintained by providing a continuous supply of
TGF-β1 [19–21]. Additionally, we have found that pro-
viding chondrocytes with TGF-β1 producing cells helps
cartilage regeneration [22]. Our pre-clinical studies
showed the production of hyaline cartilage using a mix-
ture (TG-C) of human chondrocytes (hChonJ) and irra-
diated TGF-β1 producing chondrocytes (hChonJb#7)
[23]. To elucidate the mechanism of cartilage regener-
ation, the effects of TGF-β1produced from irradiated
hChonJb#7 in TG-C on the de-differentiated chondro-
cytes were investigated. Additionally, to evaluate the
adherence of TG-C when injected directly without a
scaffold, an assessment of TG-C binding to the damaged
cartilage surface was performed. This study suggests the
mechanism of new cartilage formation by TG-C, in
which chondrocytes bound to the damaged cartilage
accumulate ECM including type II collagen and GAG
through continuous induction of TGF-β1 produced
from co-injected hChonJb#7cells. This, therefore, provides
a favourable environment for chondrocyte re-differentiation
eventually resulting in cartilage regeneration.
Methods
Cell culture
Human cartilage samples were obtained at the time of
surgery for excision of a polydactyl finger. The patient
was one year old. Cartilage tissues were obtained fromthe rudimentary excised finger, which was donated for
further experiments by parents with written consent.
The study was performed in compliance with the ethical
guidelines of the Helsinki Declaration, and was approved
by the institutional review board at the Inha University
Medical School and Hospital.
Excised cartilage tissues were rinsed with sterile phos-
phate buffered saline (PBS) and treated with collagenase
(from Clostridium histolyticum; GIBCO-BRL/Invitrogen,
Rockville, MD) in Ham’s F12 medium containing 10 %
fetal bovine serum (FBS). After collagenase treatment,
the cartilage tissues were strained to collect chondrocyte
cells. Chondrocytes were washed with PBS and cultured
in Ham’s F12 medium containing 10 % FBS [19].
The primary chondrocytes (hChonJ) and the genetic-
ally modified clone, hChonJb#7 were expanded with
Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10 % FBS and 1 % L-Glutamine in a 37 °C, 5 % CO2
atmosphere.
For micro-mass culture, 3 × 105 hChonJ cells (passage 8)
or a mixture of 3 × 105 hChonJ cells and 1 × 105 irradiated
hChonJb#7 cells (passage 18) in 20 μl of chondrogenic
medium were seeded in each well of type I collagen coated
24 well plates. After cells were allowed to adhere at 37 °C
for 1.5 h, 1 ml of chondrogenic medium was carefully
added to each well. When required, recombinant human
TGF-β1 (25 ng/ mass if not designated, eBioscience,
San Diego, CA, USA), purified human type II collagen
(25 ng/ mass, EMD Millipore, Temecula, CA, USA), or
Proteoglycans (25 ng/ mass ProteaImmun, Berlin, Germany)
was added into the seeding cell mixture. Culture medium
was changed every 3–4 days with supplemented chondro-
genic medium. For chondrogenic medium preparation,
0.1 mM dexamethasone, 0.17 mM ascorbic acid, 0.35 mM
proline, 1 mM Sodium pyruvate, and Insulin-transferrin-
salenous acid (1×) were supplemented into serum free
high glucose DMEM. Micro-masses were harvested on
day 7 to use for tests.
For culture and expansion of COS-1 monkey kidney
cells (ATCC CRL-1650) and Hep G2 Hepatocellular
Carcinoma (ATCC HB-8065), ATCC guidance was
followed using 10 % FBS containing DMEM and Eagle’s
Minimum Essential Medium (EMEM) respectively.
Construct of wild-type TGF-β1 and mutants
To investigate of the biological activity of TGF-β1 pro-
duced from hChonJb#7, we made four constructs as fol-
lows: wild-type TGF-β1, TGF-β1S223/225 containing a
serine at position 223 and 225 of the TGF-β1 precursor in
place of the wild-type cysteine residue, TGF-β1A84/W255
containing a alanine and tryptophan at position 84 and
255 of the TGF-β1 precursor in place of the wild-type
threonine and arginine residue, respectively, and TGF-
β1hChonJb#7 containing all of four residue mutations, which
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taining wild-type TGF-β1 and mutants, the coding region
of wild-type TGF-β1 and TGF-β1hChonJb#7 was amplified
by PCR using cDNA synthesized by the RNA of normal
chondrocyte and pKEB1 plasmid which was used to
manufacture hChonJb#7 cell line and then inserted into
the Xho I and EcoR I sites of pMSCV retroviral vector
(Clontech, CA, USA). Afterwards, TGF-β1S223/225 and
TGF-β1A84/W255 were respectively constructed from wild-
type TGF-β1 and TGF-β1hChonJb#7 constructs using a
point-mutagenesis kit according to the manufacturer’s
protocol (Agilent Technologies, CA, USA).
Western blot analysis
To confirm the expression of TGF-β1 constructs, culture
supernatant was mixed with reducing or non-reducing
(with or without β-mercaptoethanol, respectively) Tris-
Glycine sample buffer and separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Electrotransferred nitrocellulose membrane was probed
with anti-TGF-β1 antibody (Cell Signaling Technology,
Inc., Beverly, MA, USA).
TGF-β1 protein bioactivity assay
The four TGF-β1 constructs transfected Cos-1 cell
culture medium was used for TGF-β1 source to moni-
tor proliferation inhibition of Hep G2 hepatocellular
carcinoma. The concentration of TGF-β1 in the Cos-1
culture medium was measured by Enzyme-linked Im-
munosorbent Assay (ELISA) after acid activation and a
designated amount of TGF-β1, which was expected to
be if activated, was applied into Hep G2 cell culture
(seeded at a cell density of 5000 cells/well of 96 μ-well
plate). After 1 week incubation, the levels of viable cells
were measured using Cell Counting Kit-8 (CCK-8) assay
(Dojindo Molecular Technologies, Inc., Rockville, MD,
USA).
In vitro cartilage formation
Culture-expanded hChonJ (passage 8) cells were
thawed at 37 °C and washed in phosphate buffered
saline (PBS) and then resuspended in a chondrogenic
medium. Aliquots of 2.0 × 105 cells, suspended in
1 mL chondrogenic medium supplemented with 25 ng/mL
of recombinant human TGF-β1 (Peprotech, NJ, USA),
were centrifuged at 450 × g for 5 min in 15 mL poly-
propylene conical tubes. Pelleted cells were incubated
at 37 °C, 5 % CO2 atmosphere with loosened caps to
permit gas exchange. The medium was changed every
3–4 days and pellets were harvested on days 21.
Safranin-O staining and immunohistochemical stain-
ing of type II collagen were performed. This experi-
ment was performed four times, making 3 pellets
each time.Histological staining
At 21 days, pellets were embedded in optimum cutting
temperature (OCT) compound and transferred the
frozen pellet blocks to −20 °C of a Cryotome™ E cryo-
stat (Thermo Scientific, MA, USA). Blocks of the pel-
lets were cut into 3 μm thick slices using a cryostat
and mounted on glass slides. The sections were
stained with Safranin-O (S-O) for proteoglycan and
immunohistochemistry for type II collagen. For S-O
staining, sections were incubated in distilled water for
10–15 min and 0.1 % S-O solution was applied for
5 min, and then washed with distilled water. For im-
munohistochemistry, we used the Histostatin-Plus Kit
(Invitrogen, CA, USA). After sections were incubated
in distilled water for 10–15 min, washed with PBS for
10 min, and then, we performed according to the
manufacturer’s protocol. The primary antibody against
human type II collagen (EMD Millipore) was used and
incubated at 4 °C overnight.
Glycosaminoglycan (GAG) assay
The total soluble GAG of cultured micro-masses was
measured using a Blyscan sulfated glycosaminoglycan
assay kit (biocolor, Carrickfergus, County Antrim, UK).
The micro-mass in each well was washed with PBS and
then digested with papain extraction reagent for 3 h at
65 °C with 30 min interval mixing. The cell lysate from
two wells was combined into one sample and trans-
ferred to a micro-centrifuge tube. Total 6 μ-masses
were used as triplicated samples (2 μ-masses/ sample)
for each experiment. Afterwards, the manufacturer’s
protocol was followed.
Quantitative Polymerase Chain Reaction (qPCR)
Total RNA was extracted from 10 to 12 μ-masses
using TRIzol reagent (GIBCO-BRL/ Invitrogen by
Life Technologies, Grand Island, NY, USA). Reverse
transcriptase-polymerase chain reaction (RT-PCR) was
performed with a SuperScript II reverse transcriptase
(Invitrogen by Life Technologies, Grand Island, NY,
USA) and random primer mix (NEB, Ipswich, MA,
USA). For qPCR, C1000 thermal cycler system with
CFX96 real-time PCR detection systems (Bio-Rad,
Hercules, CA, USA) and IQTM SYPR® Green supermix
(Bio-Rad, Hercules, CA, USA) were used with the
following primers: type II collagen (forward, 5'-CC
CTGAGTGGAAGAGTGGAG-3', reverse, 5'-GAGGC
GTGAGGTCTTCTGTG-3'), type I collagen (forward,
5'-CGATGGCTGCACGAGTCACAC-3', reverse, 5'-C
AGGTTGGGATGGAGGGAGTTTAC-3'), GAPDH (for-
ward, 5'- TCGACAGTCAGCCGCATCTTCTTT-3', re-
verse, 5'-ACCAAATCCGTTGACTCCGACCTT-3'). The
relative mRNA levels were evaluated using the 2ΔΔC(t)
method.
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The distal end of the femurs were removed and partial
osteochondral defects (3 mm × 6 mm, 1 mm deep) were
created in the trochlear groove of the femurs of adult
rabbits. The cartilages with defects were cultured in
serum-free DMEM (Gibco by Life Technologies, Grand
Island, NY, USA) supplemented with antibiotic-
antimycotic (Gibco by Life Technologies, Grand Island,
NY, USA) for 24 h. To determine the length of time for
cell attachment to the defect area, the cartilage defect
on the femoral condyle was faced upward. CM-DiI
(Molecular probes, by Life Technologies, Grand Island,
NY, USA) labeled hChonJ and CM-DiO (Molecular
probes, by Life Technologies, Grand Island, NY, USA)
labeled irradiated-hChonJb#7 were used for the trans-
plantation. The defect was filled with TG-C (mixed
hChonJ:hChonJb#7, ratio = 3:1, 2 × 106 cells in 10 μL
PBS), and was left undisturbed for 7, 15, 20, 30, and
40 min. The femurs were then turned with the defect
side down for 10 min in a 50 ml conical tube contain-
ing PBS to washout the non-adherent cells in the cul-
ture medium. Non-adherent cells in the medium were
collected and cell number was counted. The number of
cells attached to the cartilage defects was calculated by
subtracting the non-adherent cell number from the ini-
tial cell number of 2 × 106. The cells attached to the
cartilage were observed with a fluorescent image
analyzer LAS-4000 (FujiFilm, Tokyo, Japan). The use
of blue LED with an Y515Di filter and red LED with a
R670 filter allows the direct detection of fluorescence
from CM-DiO labeled hChonJb#7 and CM-DiI labeled
hChonJ, respectively [24]. Guidelines from the Institu-
tional Animal Care and Use Committee at the Inha
University Medical School and Hospital were followed
during all animal procedures.
Results
hChonJb#7 cells produce TGF-β1 as functional as
rhTGF-β1
Cysteine 223 and Cysteine 225 of TGF-β1preprotein are
essential for dimerization and mutation of them to
Serine was known to enhance spontaneous maturation
without activation [25]. Based on this observation, we
manipulated human TGF-β1 gene to bear the mutation
and isolated single clone (hChonJb#7) after transduction
into human chondrocyte (hChonJ). While we analyzed
the DNA sequence of the transduced gene in hChonJb#7,
we detected additional mutations with which the wild-
type threonine at position 84 and arginine residue at pos-
ition 255 of the TGF-β1 precursor had changed into ala-
nine and tryptophan respectively (A84/W255) in addition
to the intended mutation of Cysteine 223 and 225 into
Serine (S223/255). To determine the effects of the muta-
tions, we prepared pMSCV constructs bearing 4 differentTGF-β1variants -wild type (WT), S223/225 mutant, A84/
W255 mutant, and hChonJb#7 mutant (both S223/225
and A84/W255 mutated and designated as #7 in figures) -
and transfected them into Cos-1 monkey kidney cells
to obtain TGF-β1 preproteins released into its culture
supernatant.
To confirm their expression, TGF-β1 preproteins in
culture supernatants were revealed by SDS-PAGE in
both non-reducing and reducing conditions. In non-
reducing conditions in which disulfide bonds can be
maintained, all four variants showed the mature dimer
form of TGF-β1, which is comparable to recombinant
human TGF-β1 (rhTGF-β1), and the mature dimer was
shifted into monomer form under reducing conditions
(Fig. 1a).
To distinguish the activities of TGF-β1 variants quan-
titatively, we monitored proliferation of hepatocellular
carcinoma HepG2 cells when treated with individual
variant. This assay was based on the fact that active
TGF-β1 inhibits cell proliferation. As shown in Fig. 1b,
S223/225 mutant and #7 mutant of TGF-β1 preprotein
inhibited proliferation of Hep G2 cells more efficiently
(at least 3 times more) than WT or A84/W255 mutant
suggesting that S223/225 or #7 mutant was more effi-
ciently activated than WT or A84/W255. TGF-β1 prepro-
tein produced from hChonJb#7 cells also showed similar
inhibitory effect on Hep G2 proliferation comparable to
that of S223/225 or #7 (Fig. 1b).
In serial dilution studies to determine IC50, TGF-β1
preprotein in hChonJb#7 cell culture supernatant showed
almost identical functional activity (<0.156 ng/ml of IC50)
with rhTGF-β1, which exists in a fully active form (Fig. 1c).
Based on these observations, we confirmed that
hChonJb#7 cells produce almost fully active TGF-β1.
TGF-β1 produced by hChonJb#7 functions on hChonJ as
effective as rhTGF-β1
In previous experiments, we showed that TGF-β1
produced from hChonJb#7 cells is equally functional
as rhTGF-β1 in inhibiting carcinoma cell proliferation.
Next, we examined whether TGF-β1 from hChonJb#7
cells is similarly effective on human chondrocytes (hChonJ
cells).
When hChonJ cells were incubated with rhTGF-β1 in
a pellet culture, a shiny white cartilage-like pellet was
formed in 2 weeks (Fig. 2a). However, if not supple-
mented with rhTGF-β1 then pellets do not form well
(data not shown). Safranin-O staining showed the pres-
ence of proteoglycan in articular cartilage-like pellets.
Type II collagen was also detected using immunohisto-
chemistry (Fig. 2b). Proteoglycan and type II collagen
are the main components of extra-cellular matrix (ECM)
abundant in articular cartilage so they are considered as
markers for articular chondrocytes. Rather than staining
Fig. 1 TGF-β1 produced from hChonJb#7 functions as rhTGF-β1. a TGF-β1gene was modified to bear WT or mutants related to hChonJb#7. Its
expression was tested by western blot using culture medium of Cos-1 cells that were transfected with individual constructs. 1: rhTGF-β1, 2: pMSCV
TGF-β1 (WT), 3: pMSCV TGF-β1 (S223/225 mutant), 4: pMSCV TGF-β1 (A84/W255 mutant), 5: pMSCV TGF-β1 (S223/225 & A84/W255 mutant,
designated #7). Upper panel is showing matured dimer of TGF-β1in a non-reducing gel that was shifted into monomer form in a reducing gel
(lower panel). b TGF-β1gene transfected Cos-1 cell culture medium or hChonJb#7 cell culture medium was used as TGF-β1source to inhibit
proliferation of Hep G2 carcinoma cells in 5 ng/ml concentration. Control; no addition of any TGF-β1, WT; wild type TGF-β1, S223/225; Serine 223
and Serin225 changed mutant TGF-β1, A84/W255; Threonine 84 and Arginine 255 changed mutant TGF-β1, #7; combined mutant of S223/225
and A84/W255, hChonJb#7; TGF-β1 contained in hChonJb#7 culture medium. The absorbance of the Y-axis increases in proportion to the number
of live cells. The error bars represent the standard deviation. c The serially diluted supernatant containing TGF-β1 in concentration of 10 ng/ml to
0.156 ng/ml was applied into Hep G2 cell culture to determine IC50 of each TGF-β1 variant
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II collagen were detected quantitatively with alterna-
tive assays such as the GAG assay and qPCR, respect-
ively, following micro-mass culture which is more
convenient culture method than pellet culture. As
shown in Fig. 2, rhTGF-β1 supplemented hChonJ
micro-masses formed approximately 4 times more
GAG compared to untreated masses. The TGF-β1 pro-
duced by hChonJb#7 exhibited a tendency to induce
GAG formation at similar bioactivity levels compared
to fully active rhTGF-β1 protein (Fig. 2c). There was a
trend in the results of qPCR experiments to detect type
II collagen mRNA levels which indicated that TGF-β1produced from hChonJb#7 cells and rhTGF-β1 both
induced type II collagen gene expression and did so at
a similar scale exhibiting approximately a 200 fold
difference compared to the negative control (Fig. 2d).
Although the type II collagen expression level in-
creased, if this was accompanied by an increase in type
I collagen expression, it would be difficult to consider
the chondrocytes as redifferentiated. Therefore, we ex-
amined the ratio of type II collagen mRNA levels over
to type I collagen mRNA levels. As shown in Fig. 2e,
the ratio also increased compared to the negative con-
trol suggesting that type II collagen gene expression
was selectively induced.
Fig. 2 TGF-β1 produced from hChonJb#7 functions on hChonJ as much as rhTGF-β1. a hChonJ were treated with rhTGF-β1 in a 15 ml
conical tube. After 3 weeks of incubation, pellets were formed in shiny and round shape (Grids: 1 mm interval). b The presence of
proteoglycan in articular cartilage-like tissues of pellets were shown using S-O staining. The existence of type II collagen was confirmed
with immunohistochemistry. The scale bar stands for 1 mm. c Different concentrations (5 ng or 25 ng/ mass) of rhTGF-β1 protein or the
culture supernatant of hChonJb#7 which contains identical amounts of TGF-β1 was added while setting up the hChonJ chondrocyte
micro-mass culture. After 1 week, total soluble GAG and sulfated proteoglycans were labeled with 1, 9-dimethylene blue and the content
was measured at 650 nm wavelength in a micro-plate reader. The Y-axis shows GAG amount formed in two micro-masses. The error bars
represent the standard deviation from three time repeated experiments. d The total RNA was isolated from the hChonJ micro-masses
and used for qPCR to measure the expression level of type II collagen. The level of type II collagen was normalized against glyceraldehede-
3-phosphate dehydrogenase (GAPDH) in each condition. The Y-axis shows fold difference of type II collagen mRNA level increased inTGF-β1
supplemented micro-masses compared to hChonJ micro-masses. The error bars represent the standard deviation from three time repeated
experiments. e The Y-axis shows the increased ratio of type II collagen against type I collagen expression levels. The error bars represent the
standard deviation from three time repeated experiments
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TGF-β1
Because the hChonJb#7 cells themselves produce type II
collagen [19], we tested whether the extra-cellular matrix
of hChonJb#7 including type II collagen and proteogly-
can could affect the phenotypic properties of hChonJ
cells when they were mixed. To test this possibility, we
added human type II collagen or proteoglycan into
micro-mass culture as media supplements and com-
pared this to rhTGF-β1. Unlike rhTGF-β1, neither type
II collagen nor proteoglycan induced type II collagen
gene expression (Fig. 3a). Next, we examined GAG accu-
mulation using the same factors used to test for type II
collagen change. hChonJ supplemented with rhTGF-β1
accumulated more GAG than the hChonJ control. How-
ever, neither type II collagen nor proteoglycan supple-
mented hChonJ micro-masses showed any additional
GAG accumulation as compared to hChonJ only control
(Fig. 3b). From these observations, we could assume the
main function of hChonJb#7 in cartilage regeneration is
as the source of active TGF-β1 to hChonJ cells.
Type II collagen and GAG production in TG-C
hChonJb#7 is genetically modified cell line produced via
retro-viral infection and recombination. Previous uses of
retroviral vectors in the clinic resulted in cases in which
the patients who had been treated with retroviral gene
therapy developed tumors, and most of these cases wereFig. 3 The main function of hChonJb#7 as the source of active TGF-β1. a T
rhTGF-β1 (25 ng/ μ-mass), purified human type II collagen (25 ng/ μ-mass)
1 week, total RNA was purified from each micro-mass and applied to qPCR
shows fold difference of type II collagen mRNA level increased inTGF-β1 su
error bars represent the standard deviation. b Micro-masses cultured in the
The error bars represent the standard deviationdue to the transduction into oncogenes [26]. Although
the modified TGF-β1 gene was not introduced into any
known oncogene in hChonJb#7, we decided to render
hChonJb#7 cells replication-incompetent as an extra
precaution. For this purpose, the hChonJb#7 cells were
irradiated with weak dosage of X-ray irradiation so that
the cell would die after completing its life span. How-
ever, it was expected to provide TGF-β1while it was
alive. To test this, we measured the quantity of TGF-β1
produced by the hChonJb#7 cells after irradiation. As
shown in Fig. 4a, a considerable amount of TGF-β1 was
detected for approximately 2 weeks while the cells
remained viable, confirming that the role of hChonJb#7
cells as TGF-β1 provider to hChonJ cells was not
impaired.
To prove that hChonJ cells can be redifferentiated by
irradiated hChonJb#7 cells, we mixed hChonJ cells and
irradiated hChonJb#7 cells in 3:1 ratio (TG-C) and cul-
tured them to form micro-masses. The 3:1 cell mixture
ratio has been used for our pre-clinical animal study and
Phase I and II clinical studies proving its efficacy and
safety for cartilage regeneration [23, 27]. Together with
rhTGF-β1, we measured type II collagen mRNA levels
and the amount of GAG accumulated in the TG-C
micro-masses to determine the hChonJ potency as
articular chondrocytes in TG-C. The type II collagen
mRNA level was approximately 200 fold higher (Fig. 4b)
and the GAG amount was also at least 4 times morehe hChonJ micro-masses were cultured with medium including
or proteoglycan human joint cartilage extract (25 ng/ μ-mass). After
to measure the type II collagen gene expression level. The Y-axis
pplemented micro-masses compared to hChonJ micro-masses. The
same method to (a) used to measure the accumulated GAG amount.
Fig. 4 Type II collagen and GAG production by TG-C. a Expression level of TGF-β1 in irradiated hChonJb#7 cells was monitored for 6 weeks after
the irradiation. b Type II collagen transcription level in hChonJ or TG-C micro-masses was determined by qPCR. Transcription level of type II colla-
gen was normalized against GAPDH in each condition. The Y-axis shows the standardized fold difference between hChonJ and TG-C. The error
bars represent the standard deviation. c GAG amount accumulated in hChonJ or TG-C micro-masses. TG-C masses accumulated about 4 times
more GAG than hChonJ masses at the week 1 time point. The error bars represent the standard deviation
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parable to those of experiments performed with fully
active rhTGF-β1 or hChonJb#7 culture supernatant
(Fig. 2c and d) and we confirmed that irradiated
hChonJb#7 cells also provided sufficient TGF-β1 to
redifferentiate the hChonJ cells in TG-C.
Adherence of chondrocytes to cartilage defects
To measure the binding ability of TG-C to cartilage,
fluorescent labeled hChonJ and hChonJb#7 cells were
placed on cartilage with partial knee defects (rabbits).
Both CM-DiI labeled hChonJ (red color) and CM-DiO
labeled hChonJb#7 (green color) were bound to the de-
fect area compared to the un-disturbed smooth area of
the cartilage (Fig. 5a). The number of bound cells in-
creased with time until it reached a plateau after 30 min
(Fig. 5b). We also performed the same experiment inhuman knee joint tissue which was collected after knee
joint replacement and observed the similar results (Data
not shown). Based on these observations, we conclude
that when TG-C is injected onto the damaged cartilage,
irradiated hChonJb#7 and hChonJ cells attached to the
lesion within 30 min and can play their role as a source
of TGF-β1 and cartilage material in order to rebuild
cartilage.
Discussion
TGF-β1 was reported to stimulate chondrogenesis and
synthesis of proteoglycan [28, 29]. However, the durabil-
ity of articular cartilage-like material for full-thickness
cartilage repair was not prolonged [30]. We speculated
that this short durability was due to the one-time supply
of TGF-β1. To provide TGF-β1 for a longer period, the
TGF-β1 gene was modified to be activated spontaneously
Fig. 5 Attachment of chondrocytes to rabbit cartilage. a TG-C cells were detected in the cartilage which has an artificial defect on the surface.
TG-C cells were labeled with fluorescent markers [CM-DiI (red color) labeled hChonJ and CM-DiO (green color) labeled irradiated hChonJb#7] and
were analyzed with an image analyzer (LAS-4000, FujiFilm). b The number of cells attached to a cartilage defect was calculated by subtracting the
non-adherent cells (collected from the culture media) from the initial number 2 × 106
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The transduced chondrocytes, hChonJb#7, were mixed
with normal chondrocytes, hChonJ, in a ratio of 1:3 as
TG-C to provide a treatment of the damaged cartilage. Re-
cently, we have successfully completed a Phase II clinical
study using TG-C. Preliminary data (not shown) from the
Phase II study have demonstrated the efficacy of TG-C in
regenerating cartilage as well as in relieving the pain and
improving joint function in osteoarthritis patients.
In this study, to elucidate the mechanism of cartilage
regeneration, the effect of TGF-β1 on type II collagen
and GAG expression in micro-mass cultures without a
scaffold was investigated. When the expressed TGF-β1variants were tested for their cell proliferation inhibitory
activity, modified TGF-β1 preprotein showed more effi-
cient inhibition than wild type TGF-β1 preprotein (Fig. 1).
The modified TGF-β1 produced from hChonJb#7 cells
had activity comparable to fully active rhTGF-β1, suggest-
ing that modified TGF-β1 preprotein was more efficiently
activated than WT preprotein.
To determine if the modified TGF-β1 produced from
hChonJb#7 cells is also effective on hChonJ cell rediffer-
entiation, we developed a micro-mass culture method
for chondrocytes and monitored the type II collagen
mRNA level and the amount of GAG, which are func-
tional markers for articular cartilage regeneration. For
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duction of GAG, the modified TGF-β1 produced from
hChonJb#7 was as effective as rhTGF-β1 (Fig. 2). When
hChonJb#7 cells were mixed hChonJ chondrocytes in
TG-C, the type II collagen mRNA and the GAG amount
was higher than for hChonJ cells alone, approximately
200 fold and 4 fold higher, respectively. The hChonJb #7
cells themselves also produce type II collagen and pro-
teoglycan. Therefore, we tested whether type II collagen
and proteoglycan could have additive effect on hChonJ
redifferentiation, revealing that there was no indication
of hChonJ redifferentiation when type II collagen or pro-
teoglycan was added individually to chondrocyte cul-
tures. Although they had no effect in changing hChonJ
internal characteristics, they might play a physical role
in adherence of the chondrocytes to the cartilage lesion.
Previously, there have been inconsistent results on the
effect of TGF-β1 on the production of type I or type II
collagen. Down-regulation of type II collagen gene ex-
pression by TGF-β1 was reported in articular chondro-
cytes [31, 32]. To the contrary, the re-appearance of type
II collagen with the treatment of TGF-β1 was also
reported [33, 34]. There have also been controversial or
contradictory studies about the clinical effects of TGF-β.
While some groups reported positive effects of TGF-β
on osteoarthritis (OA) treatment [35, 36], others showed
evidence that increased TGF-β was involved in OA pro-
gression or osteophyte formation. In addition, treatment
of murine knee joints with multiple injections of TGF-β
was reported to induce synovial fibrosis [37]. These dif-
ferences in reported results may be due to a variety of
factors including differences in TGF-β1 concentration,
differences in the stage of OA being treated, or different
injection locations. Therefore, a patients’ particular
condition may affect the type and severity of effects.
Our results from this study showed an increase in type
II collagen mRNA expression level induced by TGF-β1
with a corresponding increase in the ratio of type II
collagen to type I collagen (Fig. 2d and e). We further
examined type X collagen mRNA levels, and obtained
a similar result with type I collagen (data not shown).
Our results support the premise that TGF-β1 is more
likely to induce shifting of chondrocytes from a dedif-
ferentiated osteoarthritic status to a more articular
chondrocyte-like status. However, to preclude possible
side effects due to a prolonged supply of TGF-β1, we
rendered the hChonJb#7 cells replication-incompetent
so that they can provide TGF-β1 only for a limited
period, enough to induce the redifferentiation of
hChonJ.
It has been shown that primary or very early passages
of chondrocytes have the potential to bind to exposed
areas in a cartilage defect [38]. We confirmed here that
later passages of chondrocytes could also bind to thedamaged area of cartilage (Fig. 5). The binding results
indicate that a sufficient number of chondrocytes can
adhere to a cartilage defect to produce a matrix in a
three dimensional structure. Because this experiment
was performed ex vivo using the distal end of the fe-
murs removed from the rabbits, we cannot conclu-
sively state that the experiment fully mimics the in vivo
situation. However, the positive observations of cartil-
age formation from our pre-clinical and clinical studies
support the hypothesis that attachment of chondro-
cytes is a potential factor in the mechanism of action.
This binding ability of TG-C is very important since
the need of a scaffold to localize chondrocyte in the le-
sion can be potentially avoided. Therefore, the binding
of the cells in the chondrocyte and irradiated TGF-β1-
expressing cell mixture (TG-C) could provide a ration-
ale for the direct-injection of TG-C into a knee-joint
without any scaffold.
In addition to chondrocyte localization, the scaffold
usage was also shown to help allogeneic chondrocytes
to avoid an immunogenic response. While suspended
allogeneic chondrocytes induced immune responses,
allogeneic osteochondral plugs or tissue-engineered
grafts using allogeneic chondrocytes tolerated im-
munogenic response [39]. Especially, allograft chon-
drocytes embedded in type II collagen gel showed
repair of rabbit articular surfaces with no sign of im-
munogenic reactions [40]. Therefore we surmise,
based on the data shown in this study, that the suc-
cessful regeneration of cartilage with TG-C from our
previous studies may be due to the matrix-like effect
of the increased type II collagen and GAG produced
by the TG-C mixture. These components could have
acted as a scaffold to avoid immune response. How-
ever, further investigation into the potential shielding
from immune response by a scaffold effect should be
followed.
We are proposing a model of cartilage regeneration by
the co-injection of normal chondrocytes and irradiated
chondrocytes that express TGF-β1 (TG-C). First, when
TG-C is introduced into the knee joint, TG-C binds to
the area of defective cartilage like scaffold. Second, the
attached hChonJ produce more type II collagen and
GAG due to the influence of TGF-β1 secreted by the
hChonJb#7 cells. Third, the progression of cartilage re-
generation is being aided by compacting chondrocytes
and type II collagen–GAG matrices.
Conclusions
Our data suggest that TG-C, the mixture of human
chondrocytes and irradiated TGF-β1 producing chon-
drocytes, can function as a scaffold substitute by con-
tinuously providing type II collagen and GAG around
chondrocytes to the damaged cartilage.
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